Delving into the Latest Updates on Ribociclib Succinate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Kisqali, ribociclib, 利柏西利

+ [7]

Target

CDK4 x CDK6

Action

inhibitors

Mechanism

CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesNervous System Diseases+ [6]

Active Indication

Advanced breast cancerMetastatic breast cancerHormone receptor positive HER2 negative breast cancer+ [25]

Inactive Indication

Advanced cancerAdvanced Hepatocellular CarcinomaAdvanced Liposarcoma+ [68]

Originator Organization

Novartis Pharma AG

Active Organization

Novartis Pharmaceuticals Corp.

Novartis AG

Pfizer Inc.

+ [10]

Inactive Organization

Eisai GmbH

Array BioPharma, Inc.Roche Pharma AG

+ [1]

License Organization

The Massachusetts General Hospital

Novartis AG

Olema Pharmaceuticals, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (13 Mar 2017),

Hormone receptor positive HER2 negative breast cancer

RegulationBreakthrough Therapy (United States), Orphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC27H36N8O5

InChIKeyNHANOMFABJQAAH-UHFFFAOYSA-N

CAS Registry1374639-75-4

This study is a prospective, multicenter, open-label, randomized controlled clinical trial designed to determine whether ribociclib plus endocrine therapy (ET) is non-inferior to adjuvant chemotherapy followed by ribociclib plus ET in patients with circulating tumor DNA (ctDNA)-negative, hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer.

Start Date01 Oct 2026

Sponsor / Collaborator

Fudan University

CTIS2026-526704-67-00

/ Not yet recruitingPhase 1/2IIT

A phase Ib/II of chemotherapy-free trial evaluating Zongertinib in combination with Ribociclib, Endocrine Therapy and Trastuzumab in patients with ER-positive/HER2-positive metastatic breast cancer - PATRICIA-3 -

Start Date01 Oct 2026

Sponsor / Collaborator-

NCT07391774

/ RecruitingPhase 3IIT

A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS Less Than or Equal to 25 (RxFINE-Low)

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy, with letrozole, anastrozole or exemestane, lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk.

Start Date10 Aug 2026

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Ribociclib Succinate

Login to view more data

100 Translational Medicine associated with Ribociclib Succinate

Login to view more data

100 Patents (Medical) associated with Ribociclib Succinate

Login to view more data

1,400

Literatures (Medical) associated with Ribociclib Succinate

01 Mar 2027·Value in Health Regional Issues

Cost-Effectiveness of Ribociclib Plus Endocrine Therapy for Premenopausal or Perimenopausal Women With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Thailand

Article

Author: Rattanachotphanit, Thananan ; Sittibodin, Surachai ; Waleekhachonloet, Onanong

OBJECTIVES:

To evaluate the cost-effectiveness of ribociclib plus letrozole as first-line therapy for premenopausal or perimenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in Thailand.

METHODS:

We developed a state-transition (Markov) model with 5 health states and 2 tunnel states, using 28-day cycles over a lifetime horizon from the public healthcare perspective. First-line progression-free survival was reconstructed from MONALEESA-7 Kaplan-Meier curves and fitted using log-normal parametric survival models. Transition probabilities incorporated progression and death as competing risks. Utilities came from Thai EuroQol 5-Dimension (EQ-5D) data, and direct medical costs were estimated based on primary data collection from tertiary hospitals (2025 US$). Outcomes included costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER). Uncertainty was assessed using 1-way and probabilistic sensitivity analyses, whereas scenario analyses varied drug prices and incorporated Asian subgroup efficacy.

RESULTS:

Ribociclib plus letrozole yielded 5.42 QALYs at US$75 324, compared with 4.06 QALYs at US$9020 for letrozole alone, with an ICER of US$48 753 per QALY, which is above Thailand's willingness-to-pay threshold of US$4842 per QALY. The ICER was most sensitive to first-line progression-free utility, ribociclib acquisition cost, and the discount rate. Applying MONALEESA-7 Asian subgroup efficacy and a 75% ribociclib price reduction reduced the ICER to US$11 621 per QALY. Sensitivity analyses confirmed the robustness of the ICERs across all scenarios.

CONCLUSIONS:

Despite clinical benefits, ribociclib plus letrozole is not cost-effective in Thailand at the current price. Price negotiation and alternative financing or risk-sharing mechanisms are warranted to expand access while preserving budget sustainability.

31 Dec 2026·Journal of Pharmaceutical Policy and Practice

Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis

Article

Author: Hamad, Anas ; Shafei, Laila ; Mohamed Ibrahim, Mohamed Izham ; Bojassoum, Salha ; Hisham Al-Ziftawi, Nour ; Elazzazy, Shereen

Background:

Several trials demonstrated improvements in clinical outcomes associated with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in breast cancer patients. The challenge remains regarding their high costs. Ribociclib and Abemaciclib are cost-effective in Qatar. Yet, their affordability was not studied. This budget impact analysis (BIA) is to assess the affordability of adopting CDK4/6 inhibitors in Qatar over five years duration (2024-2028).

Methods:

We ran a BIA to evaluate two scenarios: (1) Increasing abemaciclib's market share from 20% to 60%, replacing both palbociclib and ribociclib. (2) Assuming equal market share for both ribociclib and abemaciclib up to 80%, reducing palbociclib's share. The analysis considered treatment costs, patient population, and disease prevalence. All data were retrieved from the National Center for Cancer Care and Research, and costs were presented in Qatari Riyals (QAR). Sensitivity analyses were run to ensure the robustness of the conclusion. All results were compared to Qatar's budget threshold, which is QAR 453,822.

Results:

Based on a total of 173 patients using CDK4/6 inhibitors, increasing abemaciclib's market share to 60% yielded cumulative savings of QAR 14 million over five years, which is around QAR 14,613 per patient per year. However, equally increasing ribociclib's and abemaciclib's market share to 80% resulted in a modest budget increase, remaining within acceptable thresholds. Sensitivity analyses confirmed the robustness of these findings, showing that cost reductions and higher uptake rates further enhanced savings.

Conclusion:

Abemaciclib is a budget-saving option for HR+/HER2- breast cancer in Qatar, should it replace the market share by up to 60% over five years. In addition, ribociclib and abemaciclib are affordable treatment options if they equally contributes to up to 80% of the market share for the eligible advanced breast cancer patients. The results supported the concept of allocating CDK4/6 inhibitors as they were found to be affordable to the Qatari healthcare system.

09 Oct 2026·Science Advances

Senescent tumor cell membrane–based “time engine” nanosystem amplifies endoplasmic reticulum targeting for metastasis blockade

Article

Author: Li, Lian ; Huang, Yuan ; Kong, Jinxia ; Zhou, Zhou ; Tao, Jing ; Zhang, Fengzhi ; Wu, Jiahui ; Guo, Yuzhen ; Xing, Liyun

As an important component of biomimetic drug delivery systems, cell membrane–coated nanoparticles are widely used for subcellular delivery. However, the influence of cell membranes at different life cycles on subcellular delivery remains unexplored. Our previous study demonstrated that senescent tumor cell membrane–coated nanoparticles (SNP) displayed superior endoplasmic reticulum (ER) targeting efficiency in tumor cells. After inducing tumor cells into senescence, SNP showed greater accumulation in ER. Herein, we design a “time engine” nanosystem for amplified ER targeting: Firstly, ribociclib is encapsulated into SNP (R@SNP) to induce tumor cell senescence; then, SNP loaded with brefeldin A (B@SNP) is used to trigger ER stress. By sequential therapy, R@SNP disrupts the cytoskeleton of 4T1 tumor cells to eliminate ER-targeting barriers and remodels the tumor immune microenvironment; B@SNP boosts ER-targeting efficiency and triggers intense ER stress. Collectively, such time engine nanosystem achieves excellent ER accumulation and antimetastatic efficacy in 4T1 tumor–bearing mice, providing an innovative perspective for subcellular delivery and tumor treatment.

490

News (Medical) associated with Ribociclib Succinate

05 Oct 2026

·www.biospace.com

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort of VIKTORIA-1 and other regimens evaluated in patients with HR+/HER2- advanced breast cancer Poster presentation of sub-group analyses from the Phase 1b trial of gedatolisib plus darolutamide in patients with mCRPC MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that a late breaking rapid oral presentation and three poster presentations will be featured at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2026 being held October 23-27, 2026, in Madrid, Spain. Data from its clinical trials of gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”) locally advanced or metastatic breast cancer (“ABC”) and metastatic castration-resistant prostate cancer (“mCRPC”) will be presented. Late Breaking Rapid Oral Presentation Details: Title: VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients with HR+/HER2- advanced breast cancer (ABC) (Study 2) Presentation Number: LBA 16 Speaker: Barbara Pistilli, MD Session Title: Rapid oral 1: Breast cancer, advanced stage Room: Almeria Auditorium - Hall 9 Date: Saturday, October 24, 2026 Time: 10:15 –11:45 a.m. CEST Poster Presentation Details: Title: A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC) Presentation Numbe r : 2237P Presenting Author: Adam Sharp, MD, PhD Session Title: Poster Display session, Metastatic prostate cancer Date: Friday, October 23, 2026 Time: 3:15 p.m. – 4:00 p.m. CEST Title: Gedatolisib (Ged) vs Other Regimens Post-CDK4/6i and Endocrine Therapy (ET) in PIK3CA Wild-Type (WT) HR+/ HER2- Advanced Breast Cancer (aBC): A Network Meta-Analysis (NMA) Presentation Numbe r : 1873P Presenting Author: Sara Tolaney, MD Session Title: Poster Display session, HR+ breast cancer Date: Saturday, October 24, 2026 Time: 12:00 p.m. – 12:45 p.m. CEST Title: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib with Endocrine Therapy (ET) and Palbociclib vs ET and Ribociclib as First-Line (1L) Treatment in Patients With HR-Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer (ABC) (VIKTORIA-2) Presentation Numbe r : 57TiP Presenting Author: Giuseppe Curigliano, MD, PhD Session Title: Poster Display session, Advanced breast cancer, other Date: Saturday, October 24, 2026 Time: 12:00 p.m. – 12:45 p.m. CEST Abstracts will be published online via the ESMO website at 12:05 a.m. CEST on October 19, 2026. The posters will be presented in the Poster Area – Hall 5. Electronic versions will also be available on the ESMO 2026 virtual platform. About Celcuity Celcuity is a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK™ (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC, supported FDA approval of REVTORPYK for use in patients without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of VIKTORIA-1 have been released. VIKTORIA-2 is an ongoing Phase 3 clinical trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib plus palbociclib plus fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib plus palbociclib plus letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov . Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at . Follow us on LinkedIn and X . Contacts: For Investors: Brian Sullivan, bsullivan@celcuity.com Vicky Hahne, vhahne@celcuity.com (763) 392-0123 For investors and media: Jodi Sievers, jsievers@celcuity.com (415) 494-9924

Phase 1Phase 3Drug ApprovalPhase 2Clinical Result

29 Sep 2026

·www.pharmaceutical-technology.com

AstraZeneca to invest $2bn in Summit for ADC combination therapies

AstraZeneca and Summit agreed to a clinical collaboration to assess ivonescimab in combination with sonesitatug vedotin. Credit: Jose Eduardo Rubio / Shutterstock.com. AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific antibody ivonescimab and antibody-drug conjugates (ADCs) across multiple tumour types. Under the transaction, AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio. This will provide an estimated 12% stake in the outstanding common stock, or 10.6% on a fully diluted basis. Alongside the equity investment, the two companies agreed to a clinical collaboration to assess ivonescimab in combination with sonesitatug vedotin (Sone-Ve), an ADC targeting CLDN18.2 with a monomethyl auristatin E payload. The partners plan to begin clinical trials in gastrointestinal cancers imminently, with each party supplying its respective candidate, sharing clinical trial expenditures, and retaining independent commercial and development rights. Concurrently, a non-binding memorandum of understanding (MoU) was executed to pursue a wider global programme evaluating ivonescimab with additional AstraZeneca oncology therapies. Ivonescimab is a bispecific antibody engineered by Akeso and blocks both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). Summit holds exclusive development and commercialisation rights for Ivonescimab outside China, while Akeso retains rights in China and other regions. The therapy is approved in China for certain non-small cell lung cancer (NSCLC) patients, and a biologics license application (BLA) for EGFR-mutated NSCLC is being reviewed by the US Food and Drug Administration (FDA). AstraZeneca oncology haematology R&D executive vice-president Susan Galbraith said: “A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumour types with combinations alongside next-generation immunotherapies. “Bispecifics targeting PD-1 and VEGF are rapidly advancing in development and have the potential to improve on current immunotherapies, particularly in lung, breast and gastrointestinal cancers. “This opportunity to combine ivonescimab with AstraZeneca’s ADC portfolio, including with Sone-Ve, could enable new regimens that raise the bar for patients with cancer across the treatment landscape.” AstraZeneca licensed Sone-Ve globally from KYM Biosciences in March 2023. Earlier this month, the FDA granted accelerated approval to AstraZeneca’s Etcamah (camizestrant), used with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib), for breast cancer.

ImmunotherapyADCDrug ApprovalAccelerated Approval

16 Sep 2026

·www.fiercepharma.com

Legend Biotech names Novartis veteran Ingrid Zhang as new CEO

Legend Biotech has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its next phase of growth. Zhang officially took the Legend CEO title on Sept. 15, assuming the post from interim chief Alan Bash, who has now returned to his role as president of Carvykti. Bash temporarily filled the position after then-CEO Ying Huang, Ph.D., abruptly resigned in July before quickly re-emerging as the CEO of a startup called K2 Therapeutics. Zhang joined Legend after a 15-year tenure at Novartis, most recently serving as chief commercial officer for Novartis’ ex-U.S. international business. Prior to that, she had held positions at AstraZeneca, Pfizer and McKinsey. Hiring a Big Pharma executive underscores Legend’s global ambition. In the second quarter of 2026, Johnson & Johnson-partnered Carvykti generated $657 million in sales, driven by 32% year-over-year growth in the U.S. and 128% expansion ex-U.S. as the multiple myeloma drug reached 19 global markets. Thanks to that Carvykti growth, Legend posted its first profit during the quarter with $63 million in adjusted net income. Zhang spent most of her Novartis time in China. Before moving to the Novartis International job mid-2024, she oversaw 17% year-over-year growth at constant currencies for Novartis’ China business in 2023 to about $3.3 billion sales. Legend likely landed Zhang before Sept. 15. About a month ago, reports in China cited a Novartis internal communication dated Aug. 19 stating that Zhang had decided to leave the Swiss pharma in pursuit of an external opportunity. Zhang confirmed his departure from Novartis in a LinkedIn post over the past weekend. The post gave a hint at what the Big Pharma veteran might focus on next for Legend. “In Poland, I learned the lesson that has stayed with me ever since: a breakthrough medicine means nothing until a patient can actually access it. That truth shaped how I've led ever since,” Zhang wrote, referring to a two-year stint she had spent as Novartis’ country president in Poland. Before Zhang’s promotion to Basel, Novartis had just won national coverage in China for its breast cancer drug Kisqali, a key growth driver for the company. Zhang will now lead Legend’s shift from overcoming supply constraints to maximizing Carvykti’s commercial potential and meeting full market demand, just as new competitors emerge. With more than 3,000 employees, Legend currently boasts as the largest standalone cell therapy company. In a Sept. 15 statement, Legend Chairman Frank Zhang, Ph.D., highlighted Zhang’s “strategic vision, operational discipline, and experience leading complex global businesses.” “It is a privilege to join Legend Biotech at an important moment in the company’s growth,” Zhang said in a statement. “Legend Biotech has established itself as a global leader in cell therapy through its commitment to scientific innovation, operational excellence, and transforming outcomes for patients. I look forward to working with the talented team at Legend to build on this strong foundation, advance our pipeline, expand our impact, and execute on our long-term growth strategy.” According to a securities filing (PDF) by Legend, the company’s employment agreement with Zhang includes an annual base salary of $950,000, plus a discretionary annual cash bonus with a target of 90% of her base salary. In a welcome package, Zhang will receive a restricted stock award worth at least $10 million and a signing bonus of $150,000.

Executive Change

100 Deals associated with Ribociclib Succinate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10979	Ribociclib Succinate	L01XE L01E	DB11730

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Advanced breast cancer	Canada	Novartis Pharmaceuticals Canada, Inc.	02 Mar 2018
Metastatic breast cancer	Canada	Novartis Pharmaceuticals Canada, Inc.	02 Mar 2018
Hormone receptor positive HER2 negative breast cancer	United States	Novartis Pharmaceuticals Corp.	13 Mar 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced HER2-Positive Breast Carcinoma	Phase 3	United States	Novartis AG	28 Mar 2022
Advanced HER2-Positive Breast Carcinoma	Phase 3	Portugal	Novartis AG	28 Mar 2022
Advanced HER2-Positive Breast Carcinoma	Phase 3	Spain	Novartis AG	28 Mar 2022
Early Stage Breast Carcinoma	Phase 3	-	Novartis Pharmaceuticals Corp.	31 Mar 2018
HER2-negative breast cancer	Phase 3	Italy	Novartis Pharmaceuticals Corp.	02 Feb 2018
Leukodystrophy, Hypomyelinating, 6	Phase 3	Italy	Novartis Pharmaceuticals Corp.	02 Feb 2018
Locally advanced breast cancer	Phase 3	Italy	Novartis Pharmaceuticals Corp.	02 Feb 2018
Breast Cancer	Phase 3	United States	Novartis Pharmaceuticals Corp.	07 Jun 2017
Advanced cancer	Phase 3	United States	Novartis Pharmaceuticals Corp.	30 Nov 2016
Advanced cancer	Phase 3	Argentina	Novartis Pharmaceuticals Corp.	30 Nov 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06830720 (CAROLEEN, ESMO2026)	Not Applicable	Early Stage Breast Carcinoma Adjuvant HR+ \| HER2-	1,304	ribociclib + aromatase inhibitor ± LHRH	dmnvclzuah(tncwznrxvv) = nbqgddxayc bemhwipjvz (yzlugsznnd, 12.3) View more	Positive	23 Oct 2026
				abemaciclib + ET ± LHRH	dmnvclzuah(tncwznrxvv) = xllmwxhsnz bemhwipjvz (yzlugsznnd, 12.5) View more
NCT03944434 (FACILE, ESMO2026)	Phase 2	Hormone receptor positive HER2 negative breast cancer First line HR+/HER2-	96	Ribociclib plus a non-steroidal aromatase inhibitor	rtflwlwdni(xxiidkaynh) = gyllycgfce awzlmsbuqq (scodpwhvgs, 70.2 - 84.5) View more	Positive	23 Oct 2026
RIBANNA (ESMO2026)	Not Applicable	Advanced breast cancer First line HR+ \| HER2-	1,849	ribociclib + endocrine therapy (ProR (PFS > 3 years))	cddqzmahwj(yscquhaxca) = xysysvvxdf fccggxpiqa (iggvkvnvkm ) View more	Positive	23 Oct 2026
				ribociclib + endocrine therapy (non-ProR)	cddqzmahwj(yscquhaxca) = wjzsyfokvq fccggxpiqa (iggvkvnvkm ) View more
NCT06375707 (ESMO2026)	Phase 2	Hormone receptor positive HER2 negative breast cancer HR+ \| HER2-	151	Ribociclib + Endocrine Therapy	rcnjpogxup(acxsreljnl) = avhlcfmzdc fzbvgwqjdb (ktsabljkzf ) View more	Positive	23 Oct 2026
				Chemotherapy	rcnjpogxup(acxsreljnl) = pbfdneowev fzbvgwqjdb (ktsabljkzf ) View more
NCT03701334 (NATALEE, ESMO2026)	Phase 3	HR+/HER2−	2,526	ribociclib+NSAI	fthwbqftvv(htgfmqatgp) = mbumlysvho fuzkvhcwox (mzagtqxrup ) View more	Negative	23 Oct 2026
				NSAI	-
ESMO2026	Not Applicable	Hormone receptor positive HER2 negative breast cancer	815	Palbociclib + endocrine therapy	tsgfqpggkd(puxozxytjt) = mnzuublvgm gczudwyxwh (nsxprjjdqu ) View more	Positive	23 Oct 2026
				Ribociclib + endocrine therapy	tsgfqpggkd(puxozxytjt) = xspvbghllf gczudwyxwh (nsxprjjdqu ) View more
ESMO2026	Not Applicable	Metastatic breast cancer	299	Palbociclib (PAL)	vkcgefhihk(epetqqiqgz) = hyuaiorrcu aknfczbmxi (jbrcnjerou ) View more	Positive	23 Oct 2026
				Ribociclib (RIB)	vkcgefhihk(epetqqiqgz) = jdfbirhtfl aknfczbmxi (jbrcnjerou ) View more
ESMO2026	Not Applicable	Hormone receptor positive HER2 negative breast cancer First line	331	Palbociclib+ET	wrmrvuezff(cznbdprnal) = czmuavfjty qvjvznbtry (cehuxbtgpw, 28.8 - 63.5) View more	Positive	23 Oct 2026
				Ribociclib+ET	wrmrvuezff(cznbdprnal) = asszrbadqn qvjvznbtry (cehuxbtgpw, 46.6 - 71.1) View more
NCT05452213 (CAPTOR, ESMO2026)	Phase 4	Hormone receptor positive HER2 negative breast cancer First line HR Positive \| HER2 Negative	1,071	Ribociclib + Endocrine Therapy (Endocrine-Resistant)	jilahiktoh(oalwqhksmu) = bmapdujoyp nfkrbthbjy (tgymtkuhuu, 13.4 - 19.3)	Positive	23 Oct 2026
				Ribociclib + Endocrine Therapy (Endocrine-Sensitive)	jilahiktoh(oalwqhksmu) = jsluofulmo nfkrbthbjy (tgymtkuhuu, 25.5 - 33.6)
Ribo-Age (ESMO2026)	Not Applicable	Advanced breast cancer First line HR+/HER2-	486	Ribociclib + NSAI (<70 years old)	zedvvbwcwz(qrgdcdsduw) = fwydwsjjtz iluzopwfsp (kxzzmcedtq ) View more	Positive	23 Oct 2026
				Ribociclib + NSAI (≥70 years old)	zedvvbwcwz(qrgdcdsduw) = nydyoahxco iluzopwfsp (kxzzmcedtq ) View more